CORD BLOOD the focus of world-first clinical trial for treatment of COVID-19

Channel 7 News have reported cord blood-derived cells are being used in a world first clinical trial for COVID-19.

Monash University and Monash Health are undertaking the trial for severe COVID-19 patients who are anticipated to improve within 24 hours of cord blood treatment.

Key information:

• Umbilical cord derived cells will be expanded for adult doses
• Cord blood derived cells aim to significantly decrease the amount of oxygen needed by patients during hospital stays, and will accelerate recovery times
• Cord blood cells have anti-inflammatory and immunomodulatory properties that will impact respiratory disorders Covid-19 patients face
• 24 patients will take part in the Phase 1 trial

Click here to read more on 7news.